Literature DB >> 8418163

In vitro inhibition of Borrelia burgdorferi growth by antibodies.

A Sadziene1, P A Thompson, A G Barbour.   

Abstract

Function-oriented immunoassays, such as complement fixation and neutralization, are not commonly used in the study of the Lyme disease agent, Borrelia burgdorferi. To determine whether such assays provide information additional to matrix-based methods, such as ELISA, polyclonal antisera and monoclonal antibodies were examined for their abilities to agglutinate viable borreliae and inhibit their in vitro growth in microtiter plates. Different strains of B. burgdorferi in both high and low passage were examined, and the related spirochete Borrelia hermsii and antibodies to it served as controls. Agglutination and complement-independent inhibition of growth with polyclonal sera from rats, mice, and humans and with monoclonal antibodies to outer membrane proteins OspA and OspB was demonstrated. Growth inhibition was obtained with Fab fragments as well as with whole IgG molecules. In comparison with an ELISA using whole cells, the growth inhibition and agglutination assays were generally more specific.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8418163     DOI: 10.1093/infdis/167.1.165

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  64 in total

1.  In vitro and in vivo neutralization of the relapsing fever agent Borrelia hermsii with serotype-specific immunoglobulin M antibodies.

Authors:  A G Barbour; V Bundoc
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

Authors:  D A Jobe; N Rawal; R F Schell; S M Callister
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

Review 3.  Spirochaetal lipoproteins and pathogenesis.

Authors:  D A Haake
Journal:  Microbiology       Date:  2000-07       Impact factor: 2.777

4.  In vitro assessment of antiborrelial activity of OspA vaccine sera.

Authors:  Paul T Fawcett; Carlos D Rose; Kathleen M Gibney
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 5.  Host-pathogen interactions in the immunopathogenesis of Lyme disease.

Authors:  L T Hu; M S Klempner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

6.  Identification of Borrelia burgdorferi outer surface proteins.

Authors:  Chad S Brooks; Santosh R Vuppala; Amy M Jett; Darrin R Akins
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

7.  Differential immune responses to Borrelia burgdorferi in European wild rodent species influence spirochete transmission to Ixodes ricinus L. (Acari: Ixodidae).

Authors:  K Kurtenbach; A Dizij; H M Seitz; G Margos; S E Moter; M D Kramer; R Wallich; U E Schaible; M M Simon
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

Authors:  Y F Chang; M J Appel; R H Jacobson; S J Shin; P Harpending; R Straubinger; L A Patrican; H Mohammed; B A Summers
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Borrelia burgdorferi changes its surface antigenic expression in response to host immune responses.

Authors:  Fang Ting Liang; Jun Yan; M Lamine Mbow; Steven L Sviat; Robert D Gilmore; Mark Mamula; Erol Fikrig
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

10.  The 39-kilodalton protein of Borrelia burgdorferi: a target for bactericidal human monoclonal antibodies.

Authors:  M Scriba; J S Ebrahim; T Schlott; H Eiffert
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.